News

Novo Nordisk: It's Not Been This Cheap For Many Years
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...
The Globe and Mail4h
NVO Earnings: Novo Nordisk Stock Rises Despite Cutting Fiscal 2025 Outlook
Unfortunately, NVO’s advanced obesity drug, CagriSema has failed to display favorable results during its drug trials, putting a dent on Novo Nordisk’s ambitions. Despite the odd0073, the company plans ...
Zealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call Transcript
Zealand Pharma A/S ( OTCPK:ZLDPF) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Adam Lange - Vice President, Investor Relations Adam Steensberg - President & Chief Executive Officer David ...